Lung Neoplasms
|
0.360 |
Biomarker
|
group |
CTD_human |
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas.
|
19801978 |
2009 |
Lung Neoplasms
|
0.360 |
AlteredExpression
|
group |
BEFREE |
Furthermore, we assessed the associations of serum SOX2 levels with clinical existing lung tumor markers, such as squamous cell carcinoma antigen, cytokeratin fragment 21-1, and neuron-specific enolase.
|
24126941 |
2013 |
Lung Neoplasms
|
0.360 |
AlteredExpression
|
group |
BEFREE |
Established lung tumors retained SOX2 expression.
|
24746758 |
2014 |
Lung Neoplasms
|
0.360 |
AlteredExpression
|
group |
BEFREE |
In addition, histological staining of lung tumor sections showed reduction in SOX2 expression was associated with inhibition markers of epithelial-to-mesenchymal transition.
|
30831275 |
2019 |
Lung Neoplasms
|
0.360 |
Biomarker
|
group |
BEFREE |
In the current studies, we examined for the first time a possible role of AnxA2 in regulating SA100A10 and SOX2 in promoting a resistant phenotype of lung tumors derived from H1650 SP cells.
|
24727000 |
2014 |
Lung Neoplasms
|
0.360 |
AlteredExpression
|
group |
BEFREE |
Expression of Sox2, frequently amplified in human SCC, specifically cooperates with loss of Lkb1 to promote squamous lung tumors.
|
24953650 |
2014 |
Lung Neoplasms
|
0.360 |
AlteredExpression
|
group |
BEFREE |
SOX2 expression is associated with poor prognosis in lung cancer patients; moreover, SOX2, EGFR, and BCL2L1 expression levels were significantly correlated in lung tumors.
|
23940081 |
2013 |
Brain Neoplasms
|
0.350 |
Biomarker
|
group |
BEFREE |
Equally important, our data suggests that increases in the expression of SOX2 during brain tumor progression are likely to be linked closely with changes in other critical genes that work in concert with SOX2 to enhance the tumorigenicity of brain tumors.
|
22937156 |
2012 |
Brain Neoplasms
|
0.350 |
Biomarker
|
group |
BEFREE |
Understanding the functional differences of Sox2 between glioma-initiating cells and normal neural stem cells would contribute to therapeutic approach for treatment of brain tumors.
|
20537983 |
2010 |
Brain Neoplasms
|
0.350 |
Biomarker
|
group |
CTD_human |
A novel brain tumour model in zebrafish reveals the role of YAP activation in MAPK- and PI3K-induced malignant growth.
|
27935819 |
2017 |
Brain Neoplasms
|
0.350 |
Biomarker
|
group |
BEFREE |
To further explore the role of Sox2, we performed in vitro analysis with brain tumor stem cells (BTSCs) and established glioma cell lines.
|
22069467 |
2011 |
Brain Neoplasms
|
0.350 |
AlteredExpression
|
group |
BEFREE |
Furthermore, miR-21 and SOX2 showed up-regulation and overlapping expression pattern in RCAS/tv-a generated mouse brain tumor specimens.
|
22931209 |
2012 |
Brain Neoplasms
|
0.350 |
AlteredExpression
|
group |
BEFREE |
Using a previously described culturing condition that selectively promotes the growth of brain tumor initiating cells, which express the stem cell markers nestin and SOX-2, we characterize the expression of α-amino-3-hydroxy-5-methyl-4-isozolepropionic acid (AMPA)-type glutamate receptor subunits in brain tumor initiating cells derived from glioblastomas.
|
23110111 |
2012 |
Esophageal Neoplasms
|
0.330 |
GenomicAlterations
|
group |
CGI |
|
|
|
Esophageal Neoplasms
|
0.330 |
GeneticVariation
|
group |
BEFREE |
SOX2-silenced squamous cell carcinoma: a highly malignant form of esophageal cancer with SOX2 promoter hypermethylation.
|
28862264 |
2018 |
Esophageal Neoplasms
|
0.330 |
AlteredExpression
|
group |
BEFREE |
Here we showed that in esophageal cancer cell lines the levels of SOX2 proteins are not directly correlated to the copy numbers of SOX2 genes and are strongly influenced by proteostasis.
|
30894683 |
2019 |
Esophageal Neoplasms
|
0.330 |
AlteredExpression
|
group |
BEFREE |
miR-625 has been reported to exhibit abnormal expression in esophageal cancer (EC), but the mechanism and functions of miR-625 in esophageal cancer remain unclear. miR-625 down-regulation and Sox2 up-regulation were validated by qRT-PCR in 158 EC samples.
|
24508466 |
2014 |
Disorder of eye
|
0.330 |
Biomarker
|
group |
BEFREE |
Screening of SOX2 was completed in 89 patients with a variety of ocular anomalies, including 28 with A/M and 61 with normal eye size and anterior segment dysgenesis (28), cataract (14), isolated coloboma (5), or other eye disorders (14).
|
20454695 |
2010 |
Disorder of eye
|
0.330 |
Biomarker
|
group |
GENOMICS_ENGLAND |
|
|
|
Disorder of eye
|
0.330 |
Biomarker
|
group |
BEFREE |
We used the new selector technique, MLGA (multiplex ligation-dependent genome amplification), to confirm deletions in two genes, SOX2 (SRY [sex determining region Y]) box 2) and OTX2 (orthodenticle homeobox 2), in individuals with developmental eye disease.
|
19641633 |
2009 |
Disorder of eye
|
0.330 |
Biomarker
|
group |
GENOMICS_ENGLAND |
|
|
|
Disorder of eye
|
0.330 |
GeneticVariation
|
group |
BEFREE |
We searched for SOX2 mutation in 24 patients with typical hippocampal sclerosis and for common variations in SOX2 in 655 patients without eye disease but with epilepsy, including 91 patients with febrile seizures, 93 with hippocampal sclerosis, and 258 with temporal lobe epilepsy.
|
16529618 |
2006 |
Sarcoma
|
0.330 |
Biomarker
|
group |
CTD_human |
SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas.
|
26343384 |
2015 |
Sarcoma
|
0.330 |
AlteredExpression
|
group |
BEFREE |
In the Ewing's sarcoma and fibromatosis samples, two sarcomas where miR-182-5p is significantly downregulated, multiple predicted targets were significantly upregulated, including HMCN1, NKX2-2, SCNN1G, and SOX2.
|
26121316 |
2015 |
Sarcoma
|
0.330 |
AlteredExpression
|
group |
BEFREE |
SOX2 expression was correlated with important clinicopathological features, including tumor stage, tumor grade, tumor architecture and the presence of glandular or sarcoma differentiation, and was an independent predictor of poor DFS and CSS.
|
31695499 |
2019 |